152 related articles for article (PubMed ID: 15168599)
21. Clinical profile of multiple myeloma and effect of thalidomide based treatment on its outcome.
Sridhar S; Dutta TK; Basu D
J Indian Med Assoc; 2011 Dec; 109(12):880-2, 887-8. PubMed ID: 23469567
[TBL] [Abstract][Full Text] [Related]
22. Patients with multiple myeloma treated with thalidomide: evaluation of clinical parameters, cytokines,angiogenic markers, mast cells and marrow CD57+ cytotoxic T cells as predictors of outcome.
Mileshkin L; Honemann D; Gambell P; Trivett M; Hayakawa Y; Smyth M; Beshay V; Ritchie D; Simmons P; Milner AD; Zeldis JB; Prince HM
Haematologica; 2007 Aug; 92(8):1075-82. PubMed ID: 17640854
[TBL] [Abstract][Full Text] [Related]
23. Pomalidomide with or without dexamethasone for relapsed/refractory multiple myeloma in Japan: a retrospective analysis by the Kansai Myeloma Forum.
Matsumura-Kimoto Y; Kuroda J; Kaneko H; Kamitsuji Y; Fuchida SI; Nakaya A; Shibayama H; Uoshima N; Yokota I; Uchiyama H; Yagi H; Kosugi S; Matsui T; Ishikawa J; Matsuda M; Ohta K; Iida M; Tanaka H; Kobayashi M; Wada K; Shimazaki C; Nomura S; Imada K; Hino M; Matsumura I; Kanakura Y; Takaori-Kondo A;
Int J Hematol; 2018 May; 107(5):541-550. PubMed ID: 29380179
[TBL] [Abstract][Full Text] [Related]
24. A pharmacokinetic study evaluating the relationship between treatment efficacy and incidence of adverse events with thalidomide plasma concentrations in patients with refractory multiple myeloma.
Kodama T; Abe M; Iida S; Ozaki S; Sakai A; Sawamura M; Shimazaki C; Miyata A; Wakayama T; Murakami H
Clin Lymphoma Myeloma; 2009 Apr; 9(2):154-9. PubMed ID: 19406727
[TBL] [Abstract][Full Text] [Related]
25. Tumor angiogenesis in the bone marrow of multiple myeloma patients and its alteration by thalidomide treatment.
Du W; Hattori Y; Hashiguchi A; Kondoh K; Hozumi N; Ikeda Y; Sakamoto M; Hata J; Yamada T
Pathol Int; 2004 May; 54(5):285-94. PubMed ID: 15086832
[TBL] [Abstract][Full Text] [Related]
26. Phase II study of melphalan, thalidomide and prednisone combined with oral panobinostat in patients with relapsed/refractory multiple myeloma.
Offidani M; Polloni C; Cavallo F; Liberati AM; Ballanti S; Pulini S; Catarini M; Alesiani F; Corvatta L; Gentili S; Caraffa P; Boccadoro M; Leoni P; Palumbo A
Leuk Lymphoma; 2012 Sep; 53(9):1722-7. PubMed ID: 22335534
[TBL] [Abstract][Full Text] [Related]
27. Bendamustine, lenalidomide and dexamethasone (BRd) has high activity as 2
Mey UJ; Brugger W; Schwarb H; Pederiva S; Schwarzer A; Dechow T; Jehner P; Rauh J; Taverna CJ; Schmid M; Schmidt-Hieber M; Doerfel S; Fischer N; Ruefer A; Ziske C; Knauf W; Cathomas R; von Moos R; Hitz F; Sauter R; Hiendlmeyer E; Cantoni N; Bargetzi M; Driessen C
Br J Haematol; 2017 Mar; 176(5):770-782. PubMed ID: 27983764
[TBL] [Abstract][Full Text] [Related]
28. Lenalidomide: a new agent for patients with relapsed or refractory multiple myeloma.
Tariman JD
Clin J Oncol Nurs; 2007 Aug; 11(4):569-74. PubMed ID: 17723971
[TBL] [Abstract][Full Text] [Related]
29. DCEP for relapsed or refractory multiple myeloma after therapy with novel agents.
Park S; Lee SJ; Jung CW; Jang JH; Kim SJ; Kim WS; Kim K
Ann Hematol; 2014 Jan; 93(1):99-105. PubMed ID: 24240976
[TBL] [Abstract][Full Text] [Related]
30. [Role of thalidomide in the treatment of multiple myeloma].
Mikala G; Jákó J; Vályi-Nagy I
Orv Hetil; 2001 Aug; 142(33):1789-98. PubMed ID: 11573449
[TBL] [Abstract][Full Text] [Related]
31. Biosimilar granulocyte colony-stimulating factor is effective in reducing the duration of neutropenia after autologous peripheral blood stem cell transplantation.
Cioch M; Jawniak D; Kotwica K; Wach M; Mańko J; Gorący A; Klimek P; Mazurkiewicz E; Jarosz P; Hus M
Transplant Proc; 2014 Oct; 46(8):2882-4. PubMed ID: 25380941
[TBL] [Abstract][Full Text] [Related]
32. Thalidomide in patients with advanced multiple myeloma: a study of 83 patients--report of the Intergroupe Francophone du Myélome (IFM).
Yakoub-Agha I; Attal M; Dumontet C; Delannoy V; Moreau P; Berthou C; Lamy T; Grosbois B; Dauriac C; Dorvaux V; Bay JO; Monconduit M; Harousseau JL; Duguet C; Duhamel A; Facon T
Hematol J; 2002; 3(4):185-92. PubMed ID: 12189564
[TBL] [Abstract][Full Text] [Related]
33. Thalidomide alone or in combination with dexamethasone in patients with advanced, relapsed or refractory multiple myeloma and renal failure.
Tosi P; Zamagni E; Cellini C; Cangini D; Tacchetti P; Tura S; Baccarani M; Cavo M
Eur J Haematol; 2004 Aug; 73(2):98-103. PubMed ID: 15245508
[TBL] [Abstract][Full Text] [Related]
34. How to manage neutropenia in multiple myeloma.
Palumbo A; Bladé J; Boccadoro M; Palladino C; Davies F; Dimopoulos M; Dmoszynska A; Einsele H; Moreau P; Sezer O; Spencer A; Sonneveld P; San Miguel J
Clin Lymphoma Myeloma Leuk; 2012 Feb; 12(1):5-11. PubMed ID: 22178143
[TBL] [Abstract][Full Text] [Related]
35. Thalidomide and hematopoietic-cell transplantation for multiple myeloma.
Barlogie B; Tricot G; Anaissie E; Shaughnessy J; Rasmussen E; van Rhee F; Fassas A; Zangari M; Hollmig K; Pineda-Roman M; Lee C; Talamo G; Thertulien R; Kiwan E; Krishna S; Fox M; Crowley J
N Engl J Med; 2006 Mar; 354(10):1021-30. PubMed ID: 16525139
[TBL] [Abstract][Full Text] [Related]
36. Low incidence of thromboembolism in relapsed/refractory myeloma patients treated with thalidomide without thromboprophylaxis in Taiwan.
Wu SY; Yeh YM; Chen YP; Su WC; Chen TY
Ann Hematol; 2012 Nov; 91(11):1773-8. PubMed ID: 22706703
[TBL] [Abstract][Full Text] [Related]
37. Phase 2 study of pegylated liposomal doxorubicin, vincristine, decreased-frequency dexamethasone, and thalidomide in newly diagnosed and relapsed-refractory multiple myeloma.
Hussein MA; Baz R; Srkalovic G; Agrawal N; Suppiah R; Hsi E; Andresen S; Karam MA; Reed J; Faiman B; Kelly M; Walker E
Mayo Clin Proc; 2006 Jul; 81(7):889-95. PubMed ID: 16835968
[TBL] [Abstract][Full Text] [Related]
38. The neutropenia induced by the thalidomide analogue CC-4047 in patients with multiple myeloma is associated with an increased percentage of neutrophils bearing CD64.
McCarthy DA; Macey MG; Streetly M; Schey SA; Brown KA
Int Immunopharmacol; 2006 Jul; 6(7):1194-203. PubMed ID: 16714224
[TBL] [Abstract][Full Text] [Related]
39. Extramedullary progression despite a good response in the bone marrow in patients treated with thalidomide for multiple myeloma.
Avigdor A; Raanani P; Levi I; Hardan I; Ben-Bassat I
Leuk Lymphoma; 2001 Aug; 42(4):683-7. PubMed ID: 11697498
[TBL] [Abstract][Full Text] [Related]
40. Lenalidomide: new drug. Myeloma: many questions remain unanswered.
Prescrire Int; 2008 Dec; 17(98):230-2. PubMed ID: 19422142
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
